{
  "docId": "019de075-fb9a-714c-b35d-12bca943aee3",
  "docSlug": "2a9ec9aa90b640f79ff73c220b20ff7d",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 57 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 57,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 16,
  "notes": "The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-fb9a-714c-b35d-12bca943aee3/6",
  "deckHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3",
  "deckJsonHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3.json",
  "deckAnchorHref": "/decks/019de075-fb9a-714c-b35d-12bca943aee3#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.4,
        "y": 0.25
      },
      "kind": "callout",
      "text": "NXC-201 Low neurotoxicity vs. ~20-30% for others",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c200a02a-7fd8-41ef-bed9-3498e3164d30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.55,
        "x": 0.32,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Neurotoxicity (%)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86bd189c-b62d-4553-ba5b-1aeb281fcf2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.96,
        "x": 0.02,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Carvykti and Abecma FDA labels, Arcellx Corporate Presentation. Assayag, N., et al. European Society for Blood and Marrow Transplantation 49th Annual Meeting. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting, 2023.. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Figures reflect cross-trial comparison and not results from a head-to head study.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97c53d55-e183-4598-8e21-27cd5977b08b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.94,
        "x": 0.03,
        "y": 0.65
      },
      "kind": "table",
      "text": "Median CRS Onset, Duration, and Patient counts",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "095acbfe-d7e5-4064-89d6-84d1eaa5e7d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "NXC-201 Is Overcoming Prolonged CRS and Neurotoxicity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03ab263f-2e72-4ed6-b5fd-e2112a05cd63",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "76d00927-2e65-45b1-a09f-29249ef6ab79",
      "evidence": "table/data: Median CRS Onset, Duration, and Patient counts",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "98ec907a-bbd5-4f1f-a9b0-62339831ab03",
      "evidence": "Direct comparison of clinical trial metrics between NXC-201 and competitors.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "4e9cfcbf-1fcc-481c-a7a9-6ab40cdca031",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Situation & Context",
      "beatSlug": "consultants-gambit-situation-context",
      "evidence": "The competitive analysis and market sizing slides provide context for the solution.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Setup",
      "parentBeatSlug": "setup"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 6,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "b538a2a7-be16-4a91-b7cb-a22c4814745a",
      "evidence": "The competitive analysis and market sizing slides showcase the solution's advantages.",
      "position": 1,
      "objective": "Why is NXC-201 a better solution?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}